Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
Autore:
Sampson, FC; Beard, SM; Scott, F; Vandenberghe, E;
Indirizzi:
Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England Univ Sheffield Sheffield S Yorkshire England S1 4DA S Yorkshire, England Res Triangle Inst Hlth Solut, Manchester, Lancs, England Res Triangle InstHlth Solut Manchester Lancs England er, Lancs, England Univ Dundee, Ninewells Hosp & Med Sch, Dept Haematol, Dundee DD1 9SY, Scotland Univ Dundee Dundee Scotland DD1 9SY t Haematol, Dundee DD1 9SY, Scotland Royal Hallamshire Hosp, Dept Haematol, Sheffield S10 2JF, S Yorkshire, England Royal Hallamshire Hosp Sheffield S Yorkshire England S10 2JF ire, England
Titolo Testata:
BRITISH JOURNAL OF HAEMATOLOGY
fascicolo: 4, volume: 113, anno: 2001,
pagine: 1015 - 1019
SICI:
0007-1048(200106)113:4<1015:COHCIF>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; RANDOMIZED CLINICAL-TRIAL; QUALITY-OF-LIFE; AUTOLOGOUS TRANSPLANTATION; ECONOMIC-ANALYSIS; THERAPY; SURVIVAL; AUTOTRANSPLANTS;
Keywords:
myeloma; cost-effectiveness; high-dose chemotherapy; transplantation; quality of life;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Sampson, FC Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Regent Court,30Regent St, Sheffield S1 4DA, S Yorkshire, England Univ Sheffield Regent Court,30 Regent St Sheffield S Yorkshire England S1 4DA
Citazione:
F.C. Sampson et al., "Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma", BR J HAEM, 113(4), 2001, pp. 1015-1019

Abstract

The cost-effectiveness of high-dose chemotherapy in multiple myeloma was considered as part of a UK National Health Service Executive regional evidence-based appraisal process. The use of high-dose chemotherapy supported by autologous stem cell transplantation in patients under 65 years of age was shown to provide a marginal benefit of 0.7 life-years over conventional chemotherapy. This corresponded to an incremental cost 'per life-year gained' figure of approximately pound 15 000, based upon initial treatment costs and trial-period data only. The use of high-dose chemotherapy in the first-line treatment of advanced multiple myeloma improves event-free and overall survival and appears to be a cost-effective treatment option.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:22:53